Literature DB >> 20547571

Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies.

Farzin Irani1, Solomon Kalkstein, Emily A Moberg, Paul J Moberg.   

Abstract

OBJECTIVE: Cognitive deficits are among the most reliable predictors of functional impairment in schizophrenia and a particular concern for older individuals with schizophrenia. Previous reviews have focused on the nature and course of cognitive impairments in younger cohorts, but a quantitative meta-analysis in older patients is pending.
METHOD: A previously used search strategy identified studies assessing performance on tests of global cognition and specific neuropsychological domains in older patients with schizophrenia and age-matched comparison groups. Both cross-sectional and longitudinal studies were included. Potential methodological, demographic, and clinical moderators were analyzed.
RESULTS: Twenty-nine cross-sectional (2110 patients, 1738 comparison subjects) and 14 longitudinal (954 patients) studies met inclusion criteria. Patients were approximately 65 years old, with 11 years of education, 53% male and 79% Caucasian. Longitudinal analysis (range 1-6 years) revealed homogeneity with small effect sizes (d = -0.097) being observed. Cross-sectional analyses revealed large and heterogeneous deficits in global cognition (d = -1.19) and on specific neuropsychological tests (d = -0.7 to -1.14). Moderator analysis revealed a significant role for demographic (age, sex, education, race) and clinical factors (diagnosis, inpatient status, age of onset, duration of illness, positive and negative symptomology). Medication status (medicated vs nonmedicated) and chlorpromazine equivalents were inconsequential, albeit underrepresented.
CONCLUSIONS: Large and generalized cognitive deficits in older individuals with schizophrenia represent a robust finding paralleling impairments across the life span, but these deficits do not decline over a 1-6 year period. The importance of considering demographic and clinical moderators in cross-sectional analyses is highlighted.

Entities:  

Mesh:

Year:  2010        PMID: 20547571      PMCID: PMC3196956          DOI: 10.1093/schbul/sbq057

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  46 in total

1.  Moderator variables of executive functioning in schizophrenia: meta-analytic findings.

Authors:  M Johnson-Selfridge; C Zalewski
Journal:  Schizophr Bull       Date:  2001       Impact factor: 9.306

2.  Schizophrenia and the myth of intellectual decline.

Authors:  A J Russell; J C Munro; P B Jones; D R Hemsley; R M Murray
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

3.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

4.  A meta-analytic review of Wisconsin Card Sort studies in schizophrenia: general intellectual deficit in disguise?

Authors:  K R Laws
Journal:  Cogn Neuropsychiatry       Date:  1999-02       Impact factor: 1.871

5.  Stability and course of neuropsychological deficits in schizophrenia.

Authors:  R K Heaton; J A Gladsjo; B W Palmer; J Kuck; T D Marcotte; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  2001-01

6.  Letter and category fluency in schizophrenic patients: a meta-analysis.

Authors:  Christina E Bokat; Terry E Goldberg
Journal:  Schizophr Res       Date:  2003-11-01       Impact factor: 4.939

Review 7.  A review of longitudinal studies of cognitive functions in schizophrenia patients.

Authors:  B R Rund
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

Review 8.  What do we know about neuropsychological aspects of schizophrenia?

Authors:  Barton W Palmer; Sharron E Dawes; Robert K Heaton
Journal:  Neuropsychol Rev       Date:  2009-07-30       Impact factor: 7.444

9.  Course of treatment response in first-episode and chronic schizophrenia.

Authors:  S R Szymanski; T D Cannon; F Gallacher; R J Erwin; R E Gur
Journal:  Am J Psychiatry       Date:  1996-04       Impact factor: 18.112

Review 10.  Longitudinal studies of cognition in schizophrenia: meta-analysis.

Authors:  Andrei Szöke; Anca Trandafir; Marie-Estelle Dupont; Alexandre Méary; Franck Schürhoff; Marion Leboyer
Journal:  Br J Psychiatry       Date:  2008-04       Impact factor: 9.319

View more
  32 in total

Review 1.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

2.  Social skills training and computer-assisted cognitive remediation in schizophrenia.

Authors:  Matthew M Kurtz; Kim T Mueser; Warren R Thime; Silvia Corbera; Bruce E Wexler
Journal:  Schizophr Res       Date:  2015-01-29       Impact factor: 4.939

3.  Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo.

Authors:  Lone Baandrup; Birgitte Fagerlund; Birte Glenthoj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-07-11       Impact factor: 5.270

4.  Biomarkers and clinical staging in psychiatry.

Authors:  Patrick McGorry; Matcheri Keshavan; Sherilyn Goldstone; Paul Amminger; Kelly Allott; Michael Berk; Suzie Lavoie; Christos Pantelis; Alison Yung; Stephen Wood; Ian Hickie
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

Review 5.  Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.

Authors:  Cassandra J Hatzipantelis; Monica Langiu; Teresa H Vandekolk; Tracie L Pierce; Jess Nithianantharajah; Gregory D Stewart; Christopher J Langmead
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-28

6.  Telomere Length and CCL11 Levels are Associated With Gray Matter Volume and Episodic Memory Performance in Schizophrenia: Evidence of Pathological Accelerated Aging.

Authors:  Leticia Sanguinetti Czepielewski; Raffael Massuda; Bruna Panizzutti; Lucas Kich Grun; Florencia María Barbé-Tuana; Antonio Lucio Teixeira; Deanna M Barch; Clarissa S Gama
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

7.  Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia.

Authors:  Xiangyang Zhang; Mi Yang; Xiangdong Du; Wei Liao; Dachun Chen; Fengmei Fan; Meihong Xiu; Qiufang Jia; Yuping Ning; Xingbing Huang; Fengchun Wu; Jair C Soares; Bo Cao; Li Wang; Huafu Chen
Journal:  Mol Psychiatry       Date:  2019-08-13       Impact factor: 15.992

8.  Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

9.  Characterizing trajectories of cognitive functioning in older adults with schizophrenia: does method matter?

Authors:  Wesley K Thompson; Gauri N Savla; Ipsit V Vahia; Colin A Depp; Ruth O'Hara; Dilip V Jeste; Barton W Palmer
Journal:  Schizophr Res       Date:  2012-12-05       Impact factor: 4.939

10.  Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?

Authors:  Emre Bora; Robin M Murray
Journal:  Schizophr Bull       Date:  2013-06-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.